Dual-product commercial story at $500M+ revenue pace, but a guidance cut and XPHOZAH reimbursement loss test whether IBSRELA alone can carry the long-term thesis

Bull

If Ardelyx successfully works with payers to streamline prior authorization and step-therapy protocols, prescription pull-through improves materially in H2 2026, demonstrating that the guidance cut was a one-time reset rather than a structural ceiling. Additionally, completion of pediatric trials could extend patent life to 2042 via the formulation patent already issued, reinforcing the long-term commercial value of the franchise and supporting a return toward the $1B target narrative.

Bear

Payer utilization management restrictions may prove durable rather than negotiable, particularly if PBMs and commercial payers continue to require failure on cheaper generic alternatives before approving tenapanor, permanently compressing addressable market size and unit volumes. The simultaneous withdrawal of XPHOZAH long-term guidance signals broad commercial execution risk across both franchises, and if IBSRELA growth continues to decelerate, the company's path to profitability—already strained by a $61.6M net loss in 2025 and rising OPEX—becomes increasingly precarious against a cash position of $281.8M.